Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
INBX Inhibrx Biosciences Inc.
- Stocks
- Healthcare
- NASDAQ: INBX
Price (delayed)
$14.63
Market cap
$211.78M
P/E Ratio
0.13
Dividend/share
N/A
EPS
$116.43
Enterprise value
$101.79M
Highlights
The debt has contracted by 49% YoY
The quick ratio has grown by 40% YoY and by 32% from the previous quarter
The revenue has shrunk by 89% YoY
Inhibrx Biosciences's gross profit has plunged by 89% YoY
Key stats
What are the main financial stats of INBX
Market
Valuations
Earnings
Shares outstanding
14.48M
Market cap
$211.78M
Enterprise value
$101.79M
Price to earnings (P/E)
0.13
Price to book (P/B)
2.24
Price to sales (P/S)
1,131.48
EV/EBIT
0.06
EV/EBITDA
0.06
EV/Sales
508.96
Revenue
$200,000
Gross profit
$200,000
Operating income
-$300.52M
Net income
$1.72B
EBIT
$1.73B
EBITDA
$1.74B
Free cash flow
-$168.75M
Per share
Balance sheet
Liquidity
EPS
$116.43
EPS diluted
$115.37
Free cash flow per share
-$10.91
Book value per share
$6.52
Revenue per share
$0.01
TBVPS
$15.69
Total assets
$242.64M
Total liabilities
$148.2M
Debt
$106.53M
Equity
$94.44M
Working capital
$179.75M
Debt to equity
1.13
Current ratio
5.12
Quick ratio
4.97
Net debt/EBITDA
-0.06
Margins
Efficiency
Dividend
EBITDA margin
867,744.5%
Gross margin
100%
Net margin
861,485.5%
Operating margin
-150,262%
Return on assets
762.1%
Return on equity
1,101.2%
Return on invested capital
10,965.2%
Return on capital employed
869.9%
Return on sales
865,511.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INBX stock price
How has the Inhibrx Biosciences stock price performed over time
Intraday
2.09%
1 week
5.1%
1 month
29.7%
1 year
-11.81%
YTD
-5%
QTD
4.57%
Financial performance
How have Inhibrx Biosciences's revenue and profit performed over time
Revenue
$200,000
Gross profit
$200,000
Operating income
-$300.52M
Net income
$1.72B
Gross margin
100%
Net margin
861,485.5%
The revenue has shrunk by 89% YoY
Inhibrx Biosciences's gross profit has plunged by 89% YoY
INBX's operating income is down by 21% YoY but it is up by 9% QoQ
The operating margin has grown by 9% from the previous quarter
Price vs fundamentals
How does INBX's price correlate with its fundamentals
Growth
What is Inhibrx Biosciences's growth rate over time
Valuation
What is Inhibrx Biosciences stock price valuation
P/E
0.13
P/B
2.24
P/S
1,131.48
EV/EBIT
0.06
EV/EBITDA
0.06
EV/Sales
508.96
INBX's P/E is 20% above its last 4 quarters average of 0.1
The EPS has grown by 2.1% from the previous quarter
The price to book (P/B) is 47% higher than the last 4 quarters average of 1.5
Inhibrx Biosciences's equity has decreased by 29% QoQ
The revenue has shrunk by 89% YoY
The P/S is 79% higher than the last 4 quarters average of 618.3
Efficiency
How efficient is Inhibrx Biosciences business performance
The ROE has soared by 147% YoY but it has decreased by 11% from the previous quarter
Inhibrx Biosciences's ROIC has soared by 141% from the previous quarter
The company's return on assets rose by 7% QoQ
Dividends
What is INBX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INBX.
Financial health
How did Inhibrx Biosciences financials performed over time
Inhibrx Biosciences's total assets is 64% higher than its total liabilities
The total liabilities has contracted by 47% YoY
The quick ratio has grown by 40% YoY and by 32% from the previous quarter
The debt is 13% more than the equity
The debt to equity has plunged by 94% YoY
The debt has contracted by 49% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.